A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD (COPD)
An Open-Label Phase Followed by a Randomized, Double-Blind, Placebo-Controlled Phase in a Study Designed to Evaluate Intravenous 2-O, 3-O Desulfated Heparin (ODSH) in Subjects With Exacerbations of Chronic Obstructive Pulmonary Disease
Sponsor: Jazz Pharmaceuticals
Terminated
Interim analysis: safety without efficacy ODSH in patients with acute COPD.
Other terminated trials from Jazz Pharmaceuticals
Other Chronic Obstructive Pulmonary Disease trials with similar outcome
A PHASE2 clinical study on Chronic Obstructive Pulmonary Disease, this trial is terminated or withdrawn. The trial is conducted by Jazz Pharmaceuticals and has accumulated 12 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
-
Jan 2022 — Dec 2022 [monthly]
Terminated PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Apr 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jazz Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Częstochowa, Poland , Edmonton, Canada , Everett, United States , Gerlingen, Germany , Großhansdorf, Germany , Halifax, Canada , Hanover, Germany , Houston, United States , Katowice, Poland , Kelowna, Canada and 25 more locations